The Regulation casts a wide net. Primary regulated persons are “dealers” (cl 3(1)), defined to include manufacturers, importers, exporters, wholesale and retail dealers, authorised practitioners and pharmacists when supplying substances. Pharmacists receive the most detailed obligations: personal supply of Schedule 3 substances (cl 18), endorsement and recording of prescriptions (cll 41, 55, 88, 113), storage in safes meeting exact specifications (cl 76), and destruction of unwanted drugs only in the presence of an independent witness (cl 125A).

Authorised practitioners (medical practitioners, nurse practitioners, midwife practitioners, dentists, optometrists, podiatrists and veterinary practitioners) are affected by prescription-form, quantity and purpose rules (cll 32–34, 77–80), record-keeping (cll 38, 56, 82) and administration restrictions (cll 58–60, 120–121). Veterinary practitioners face additional labelling requirements (“FOR ANIMAL TREATMENT ONLY”) and limits on type A drugs (cl 78, cl 98).

Hospitals, private health facilities, residential care facilities and managed correctional centres are subject to chief-pharmacist, director-of-nursing and nurse-in-charge responsibilities for storage (cll 30–31A, 74–76A) and supply (cll 49–49A, 99–99A). Management companies of managed correctional centres must appoint pharmacists (or, if unavailable, authorised practitioners or nurses) to oversee storage, supply and destruction (cll 31A, 76A, 99A, 116, 128A, cl 183).

Practitioners of alternative medicine, scientifically qualified persons, ambulance officers, dive medical technicians, first-aid certificate holders, ski patrollers, registered beekeepers and masters of ships are granted limited authorisations under Appendix C and cll 6–20, but remain subject to quantity, purpose and record-keeping constraints.

Wholesalers, manufacturers and persons conducting clinical trials require licences or authorities under Part 8. Data source entities (Australian Health Practitioner Regulation Agency, eRx, Fred IT, Medication Knowledge, MediSecure and prescribed prescription-exchange services) are authorised to transfer prescription data into the real-time monitoring database (cl 174F). The Secretary, inspectors, police officers and courts exercise enforcement, forfeiture and exemption powers throughout.

Patients, animal owners and members of the public are indirectly affected through restrictions on self-administration (cl 59), disclosure obligations (cl 63) and the requirement that supplies accord with recognised therapeutic standards (cll 16, 23, 34, 54, 79, 109). Residential-care-facility managers and responsible persons must ensure medication-chart records are kept (cll 24(2A), 55A(3), 119A).

In total, the Regulation directly regulates thousands of businesses, health practitioners, institutions and individuals while indirectly shaping access to medicines for the entire population of New South Wales.

Duties flow from every stage of the supply chain. Dealers must comply with current Poisons Standard labelling and child-resistant packaging (cll 7, 26, 69). Storage duties require separation from food, public inaccessibility, locked safes bolted to the structure, and refrigeration controls (cll 11–13, 29–31A, 73–76A, 128D–128F). Prescription duties include handwriting requirements (or Secretary-approved alternatives), patient or owner details, dosage confirmation for dangerous doses, and purpose-specific endorsements (cll 35, 80). Supply duties prohibit supply on cancelled, forged or expired prescriptions (cll 40, 86), require verification of prescriber identity (cl 87), and limit quantities to recognised therapeutic standards (cll 23, 54, 109). Record-keeping duties mandate drug registers with dated, signed entries for every receipt, supply, administration or use (cll 111–117), retention for two years (cl 176), and periodic stocktakes (cl 118). Administration duties require written directions, emergency protocols and post-administration review (cll 58, 120). Destruction duties require presence of witnesses, recording in registers and notification where confirmation is not received (cll 125A–128A, 128LA).

Rights are conferred by way of authorisations and exemptions. Authorised practitioners may prescribe and supply within their scope of practice (cll 32, 43, 77). Pharmacists may make emergency supplies (cll 44–45, 96–97), supply on medication charts (cl 34A) and destroy unwanted drugs in the presence of an independent witness (cl 125A). Appendix C grants possession and use rights to listed classes (ambulance officers, first-aid certificate holders, registered beekeepers, scientifically qualified persons, masters of ships, etc.). The Secretary may grant exemptions from labelling, packaging, record-keeping or authority requirements (cll 10, 28, 57, 174J). Licence and authority holders enjoy the rights conferred by those instruments subject only to their conditions (Parts 8 and 175).

The Regulation balances these duties and rights through a system of authorities (cll 170–171), licences (cll 155–169) and Secretary orders that may expand or restrict authorisations (cl 175).

Penalties are offence-specific. Minor breaches (e.g. failure to label a Schedule 3 substance with dealer details – cl 9(1)) attract 2 penalty units. Most labelling, storage, prescription and supply offences carry 10–15 penalty units (cll 7, 18, 26, 32, 39). Quantity, purpose and record-keeping offences for restricted substances or drugs of addiction carry 20 penalty units or six months’ imprisonment (cll 23, 54, 79, 109, 112). Unauthorised manufacture or supply of drugs of addiction is 20 penalty units (cl 100). False or misleading register entries attract the same maximum (cl 177).

Enforcement tools include inspector powers under s 43 of the Act (defined in cl 3(1)), seizure of goods (Part 7), forfeiture (cll 68, 150–154) and Secretary orders suspending or cancelling licences and authorities (cll 172–173). Police must be notified of forged or fraudulently obtained prescriptions (cll 40(2), 86(2)). Loss or theft of prescribed restricted substances or drugs of addiction must be reported immediately (cll 67, 124). The Regulation creates strict-liability elements in many offences (e.g. maximum number of supplies exceeded – cl 40(1)(b)) while preserving mens-rea requirements for more serious conduct (e.g. wilful destruction – cl 125(1)).

Courts may order forfeiture and destruction of seized goods (cl 68) or payment of storage and analysis costs (cl 151). The Secretary may publish notice of cancelled licences or authorities in the Gazette (cl 175(7)).

The Regulation is expressly subordinate to the Act (cl 3(1) definition of “the Act”). It cross-references the Health Services Act 1997 (definitions of Ambulance Service, public health organisation, public hospital), the Crimes (Administration of Sentences) Act 1999 (correctional centres, inmates, managed correctional centres), the Private Health Facilities Act 2007, the Health Practitioner Regulation National Law (NSW) (registration of pharmacies, health practitioners), the Charitable Fundraising Act 1991, the Pesticides Act 1999, the Stock Medicines Act 1989, the Voluntary Assisted Dying Act 2022, the Photo Card Act 2005 and the Interpretation Act 1987.

Commonwealth laws are incorporated by reference: the current Poisons Standard (cl 3(2)), Therapeutic Goods Order No. 95 (cll 7, 26, 69), the Aged Care Act 1997, the National Health Act 1953 (continued dispensing – cl 45A), and the Therapeutic Goods Act 1989 (definitions of therapeutic goods and unregistered drugs of addiction). The Regulation modifies the applied Therapeutic Goods Regulations 1990 (Part 2 – advertising) by allowing Secretary exemptions (cl 174).

It also intersects with the Drug Misuse and Trafficking Act 1985 by providing authorised persons for the purposes of that Act’s defences (cl 59(3), cl 121(1)) and with the Subordinate Legislation Act 1989 (repeal of the 2002 Regulation – cl 2).

The Regulation has been amended more than 20 times since 2008. Key recent changes include:

• 2015–2016 amendments strengthened pseudoephedrine recording (cl 24) and introduced medication-chart prescriptions (cll 34A, 55A, 119A) to reduce administrative burden in residential care while maintaining accountability.
• 2018 amendments (including 2018 (655)) updated type A drug lists, clarified dental prescribing of methadone and buprenorphine, and inserted cl 182 to preserve existing licences after reclassification of certain cannabis products.
• 2020–2022 amendments responded to the COVID-19 pandemic by allowing electronic and facsimile prescriptions for restricted substances and drugs of addiction in public and private health organisations (cll 36A, 36B, 81A) and relaxing some storage and direction requirements (cll 30, 58, 75).
• 2021 amendments inserted Part 3A (cosmetic restricted substances), Part 8A (real-time prescription monitoring – cll 174A–174J), and extensive managed-correctional-centre provisions (cll 31A, 49A, 76A, 99A, 116–117, 120, 128A, 183) to address safety, accountability and diversion risks in custodial settings.
• 2023 amendments (2023 (548)) inserted Part 4A (voluntary assisted dying substances – cll 128B–128LD), updated storage, record-keeping and destruction rules (cll 125A, 128LA–128LC), and adjusted application provisions (cll 25A, 68J) to implement the Voluntary Assisted Dying Act 2022.

These changes reflect evolving public-health priorities: pandemic preparedness, harm minimisation through real-time monitoring, safe expansion of voluntary assisted dying, and tighter controls in correctional environments.

The Regulation itself does not record specific court challenges. However, its predecessor and parallel provisions have been considered in sentencing contexts under the Drug Misuse and Trafficking Act 1985 where authorised supply has been raised as a defence. Storage and record-keeping requirements in correctional centres (cll 76A, 99A, 128A) were introduced after stakeholder consultation concerning diversion risks; no appellate controversy is noted in the text. The introduction of real-time monitoring (Part 8A) and cosmetic-use restrictions (Part 3A) attracted professional commentary regarding privacy and scope of practice, but the Regulation does not cite judicial decisions. Clause 175 orders restricting authorisations have occasionally been challenged on natural-justice grounds, but again the text is silent. The absence of reported controversy in the instrument itself suggests that most disputes are resolved at first-instance disciplinary or administrative levels rather than through published appellate litigation.

Most practitioners assume that once a prescription is validly issued it can be dispensed at any time. Clause 40(1)(g) imposes strict time limits: medication-chart prescriptions expire after four months, prescribed-restricted-substance prescriptions after six months, and ordinary restricted-substance prescriptions after 12 months. Pharmacists who overlook these cut-offs commit an offence even if the prescriber intended ongoing therapy.

Another common misconception is that electronic prescribing automatically satisfies handwriting requirements. Clause 35(2A) still requires either handwriting or Secretary-approved electronic formatting; many commercial systems have not yet received formal approval, exposing pharmacists to cl 39 offences.

Storage of refrigerated drugs of addiction is a trap. Clause 76(3A) and cl 76A(4) permit refrigeration only if the refrigerator is in a non-public area, bolted down, locked when not in use, and used solely for scheduled substances or therapeutic goods. Many pharmacies inadvertently breach these cumulative conditions.

The “independent witness” requirement for pharmacist destruction of drugs (cl 125A(3)) excludes family members, employees at the same pharmacy and pharmacists with a financial interest. Compliance requires advance planning; weekend or after-hours destruction can be impossible without breaching the clause.

Appendix C authorisations are narrowly construed. A first-aid certificate holder may possess adrenaline auto-injectors but only if trained by an approved organisation; a generic first-aid certificate is insufficient (cl 13). Similarly, registered beekeepers may use oxytetracycline only with a written recommendation from the Secretary of the Department of Industry, Skills and Regional Development (cl 16).

Real-time monitoring obligations (Part 8A) apply only to electronic systems connected to approved data-source entities. Practitioners using paper or non-connected software may believe they are exempt, yet cl 174D–174E still require recording if the system is capable of connection. The Secretary’s power to exempt (cl 174J) is discretionary and not automatically granted.

Finally, the two-year retention period (cl 176(3)) runs from the latest relevant date — not the date the first entry was made. A register containing a single entry from 1 January 2022 must be kept until 1 January 2024 even if all other entries are decades old.

Compliance begins with a gap analysis of all scheduled substances held on premises. Map each substance to its schedule, confirm the applicable Part of the Regulation, and prepare written procedures covering receipt, storage, prescribing, supply, administration, recording and disposal.

Maintain a current copy of the Poisons List, the current Poisons Standard and Therapeutic Goods Order No. 95. Update procedures whenever amendments are gazetted (cl 3(1) definition of “current Poisons Standard” expressly incorporates changes from time to time).

For pharmacies and hospitals, calibrate safes and refrigerators to the exact specifications in cll 76 and 76A. Install continuous temperature monitoring with alarms for refrigerated drugs. Appoint a responsible pharmacist (or authorised practitioner where permitted) to sign off on all drug-register entries and stocktakes (cll 116–118).

Implement a prescription-validation checklist: confirm handwriting or approved electronic format, patient/owner details, dosage confirmation for high-risk prescriptions, maximum repeats, intervals, and expiry dates (cll 35, 80, 39–40, 85–86). Scan or photocopy all prescriptions for Schedule 8 and special restricted substances and store separately (cll 42, 89).

For real-time monitoring, ensure all electronic prescribing and dispensing software is connected to an approved data-source entity and that staff are trained to record the mandatory fields in cll 174D–174E. Run monthly exception reports to identify prescriptions that should have generated database entries but did not.

Develop a destruction protocol that satisfies cll 125–128A, including availability of independent witnesses and dual-signature register entries. For voluntary assisted dying substances, maintain separate steel-box storage, chain-of-custody records and authorised-disposer protocols (cll 128D–128LD).

Conduct annual staff training on cl 137–143 (personal cleanliness and hygiene when handling exposed substances) and cl 175 (Secretary orders restricting authorisations). Keep records of training for audit purposes.

Finally, establish a relationship with the Pharmaceutical Services Unit of the Ministry of Health. Seek written confirmation of any novel interpretation (e.g. whether a particular electronic system satisfies cl 35(2A)) and retain that confirmation as a compliance defence. Review all procedures whenever the Regulation is amended or a new Appendix is inserted. A robust, documented compliance system not only meets legal obligations but also reduces professional indemnity risk and protects public safety.